Video

Dr. Bekaii-Saab on the Uptake of Precision Medicine in CRC

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the uptake of precision medicine in colorectal cancer (CRC).

Personalized medicine is a growing treatment approach for patients with CRC, says Bekaii-Saab. For example, targeted therapies for patients with BRAF, HER2, or KRAS G12C mutations are showing promise in this space, Bekaii-Saab says.

However, after frontline therapy or for patients who do not harbor actionable alterations, cytotoxic chemotherapy remains the standard of care for patients with CRC, Bekaii-Saab explains. In the third- and later-line settings, oral therapies, such as TAS-102 (trifluridine/tipiracil; Lonsurf) or regorafenib (Stivarga), are standard options for patients with relapsed/refractory disease, concludes Bekaii-Saab.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO